Overview

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Status:
Not yet recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

To explore the efficacy and safety of Fruquintinib combined with Sintilimab and XELOX in the first-line treatment of unresectable advanced metastatic gastric or gastroesophageal junction adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Second Affiliated Hospital of Nanchang University

Treatments:

Capecitabine
Oxaliplatin